Biological Aging and Survival Outcomes in Patients With Advanced Non–Small Cell Lung Cancer Receiving Systemic Therapy

Nov 3, 2025Clinical lung cancer

Biological Aging and Survival in Advanced Lung Cancer Patients Receiving Treatment

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

Higher biological age (≥79.1 years) is independently associated with shorter overall survival in patients with advanced non-small cell lung cancer.

Chronological age (≥75 years) did not show the same predictive value for overall survival.
Biologically older patients in the immune checkpoint inhibitor cohort had significantly worse overall survival compared to biologically younger patients.
BioAge acceleration was identified as an independent prognostic factor for survival in the immune checkpoint inhibitor cohort.
No significant relationships were found between biological age, BioAge acceleration, or chronological age and the risk of immune-related adverse events.

AI simplified

BACKGROUND: Chronological age alone does not adequately capture inter-individual variability in the health status and treatment outcomes of patients with advanced non-small cell lung cancer (NSCLC). Biological age, calculated using routine clinical biomarkers (BioAge), may offer superior prognostic value.

PATIENTS AND METHODS: A retrospective analysis was conducted on 138 patients treated with immune checkpoint inhibitors (ICIs; ICI cohort) and 154 ICI-naïve patients treated with chemotherapy (chemotherapy cohort). BioAge was calculated using chronological age and seven clinical biomarkers. BioAge acceleration (BioAgeAccel) was defined as the residual derived from the linear regression of BioAge on chronological age. The Kaplan-Meier method and Cox proportional hazards model were used for survival analyses. In the ICI cohort, associations with immune-related adverse events (irAEs) development were evaluated using competing risk regression.

RESULTS: Higher BioAge (≥79.1 years) was independently associated with shorter overall survival (OS) in both cohorts, whereas chronological age (≥75 years) was not. In the ICI cohort, biologically older patients demonstrated significantly worse OS than biologically younger patients, and BioAgeAccel was an independent prognostic factor. However, the BioAgeAccel was not associated with OS in the chemotherapy cohort. No significant associations were observed between BioAge, BioAgeAccel, or chronological age and the risk of irAEs.

CONCLUSION: Biological age is a robust prognostic factor for advanced NSCLC. BioAgeAccel has additional prognostic value, particularly in the context of immunotherapy. Incorporating biological age metrics into clinical practice may improve patient stratification and support individualized treatment decisions.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Biological Aging and Survival Outcomes in Patients With Advanced Non–Small Cell Lung Cancer Receiving Systemic Therapy

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief